Trial Profile
Clinical And Radiological Response Among Patients With Multiple Sclerosis Who Switched From Natalizumab To Fingolimod: Experience from a centre in Spain
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 Jun 2015
Price :
$35
*
At a glance
- Drugs Fingolimod (Primary) ; Natalizumab
- Indications Multiple sclerosis
- Focus Therapeutic Use
- 09 Jun 2015 New trial record
- 25 Apr 2015 Results (Risk of Rebound) presented at the 67th Annual Meeting of the American Academy of Neurology.
- 25 Apr 2015 Results (Clinical And Radiological Response) presented at the 67th Annual Meeting of the American Academy of Neurology.